Skip to Main Content

| Download (.pdf) | Print
2-D two-dimensional
3-D three-dimensional
3-D-CRT three-dimensional conformal radiotherapy
5HT 5-hydroxytryptamine
5FU 5-fluorouracil
AA anti-androgen
ADT androgen deprivation therapy
AIPC androgen-independent prostate cancer
AMACR Alpha-methylacyl coenzyme A racemace
ANN artificial neural networks
AR androgen receptor
ASCENT AIPC Study of Calcitriol Enhancing Taxotere
ASAP atypical small acinar proliferation suspicious for but not diagnostic of malignancy
ASAPB atypical small acinar proliferation suspicious for but not diagnostic of malignancy, favour benign
ASAPH atypical small acinar proliferation highly suspicious for but not diagnostic of malignancy
ASAPS atypical small acinar proliferation suspicious for but not diagnostic of malignancy
ASTRO American Society for Therapeutic Radiology and Oncology
ATBC Alpha-Tocopherol, Beta-Carotene Cancer Prevention Trial
AUC area under the curve
BAP bone-specific alkaline phosphatase
BED biological effective dose
bNED biochemical no evidence of disease
BMI body mass index
BPH benign prostatic hyperplasia
BPI Brief Pain Inventory
BFS biochemical free survival
BOO bladder outflow obstruction
BRFS biochemical recurrence free survival
CALGB Cancer and Leukemia Group B
CARET beta-Carotene and Retinol Efficacy Trial
CART classification and regression trees
CaPSURE Cancer of the Prostate Strategic Urologic Research Endeavor
CIS carcinoma in situ
CPA cyproterone acetate
CT computed tomography
CTLA4 cytotoxic T lymphocyte-associated protein 4
CTX cross-linked C-terminal
DEXA dual energy X-ray absorptiometry
DHA docosahexaenoic acid
DHT dihydrotestosterone
DRE digital rectal examination
DTPA diethylenetriamine pentaacetic acid
DVT deep vein thrombosis
EBRT external beam radiation therapy
EDTMP ethylene-diamine-tetra-methylene-phosphonate
EGF epidermal growth factor
ECOG Eastern Cooperative Oncology Group
EGFR epidermal growth factor receptor
EORTC European Organisation for Research and Treatment of Cancer
EORTC QLQ European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire
EPA eicosapentaenoic acid
EPC Early Prostate Cancer study
EPCA Early Prostate Cancer Antigen
ERSPC European Randomized Study of Screening for Prostate Cancer study
ESCC epidural and spinal cord compression
ET endothelin
EZH2 enhancer of zeste homolog 2
FA fatty acids
FACT–P Functional Assessment of Cancer Therapy – Prostate
FFF freedom from failure
GMCSF granulocyte–macrophage colony-stimulating factor
GnRHa gonadotrophin-releasing hormone agonists
GTCs green tea catechins
HBI hemi-body irradiation
HCAs heterocyclic amines
HDAC histone deacetylase
HDR high dose rate
H&E haematoxylin and eosin
HEDP hydroxyethylene diphosphonate
HER human epidermal growth factor receptor
HIFU high-intensity focused ultrasonography
HR hazard ratio
HRPC hormone-refractory prostate cancer
HRQOL health-related quality of life
ICU intensive care unit
IGF insulin-like growth factor
IGFBP insulin-like growth factor-binding proteins
IHT intermittent hormonal therapy
IL interleukin
IMRT intensity-modulated radiotherapy
IVU intravenous urography
LDH lactate dehydrogenase
LHRH luteinizing hormone releasing-hormone
LHRHa luteinizing hormone-releasing hormone agonist
LMN lower motor neurone
LNI lymph node invasion
LUTS lower urinary tract symptoms
MAB maximal androgen blockade
MAG mercaptoacetyltriglycine
MARS multiple adaptive regression splines
MCM-5 minichromosome maintenance 5
MDP methylene diphosphonate
MFA monounsaturated fatty acids
MP mitoxantrone and prednisolone
MRC Medical Research Council
MRI magnetic resonance imaging
MRP multidrug-resistant protein
MUSE Medicated Urethral System for Erection
NHT neoadjuvant hormonal therapy
NICE National Institute for Clinical Excellence
NNT number needed to treat
NPC Nutritional Prevention of Cancer trial
NTX cross-linked N-terminal
OBD optimal biological dose
OME oral ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.